Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment

Sarah E Thomas; Marieke M B Seyger; Josje E Mangnus; Marisol E Otero; Antoni H Gostynski; Marcellus D Njoo; Paul M Ossenkoppele; Inge M Haeck; Judith H J Hendricksen-Roelofzen; John E M Körver; Sharon R P Dodemont; Ron A Tupker; Maartje A M Berends; Lizelotte M J T Weppner-Parren; Romy R M C Keijsers; Annet M Oostveen; Bas Peters; Roland Mommers; Martijn B A van Doorn; Milan Tjioe; Wendelien R Veldkamp; Astrid L A Kuijpers; Marloes M Kleinpenning; Elke M G J de Jong; Juul M P A van den Reek

doi:10.1007/s40257-024-00868-x

Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment

Am J Clin Dermatol. 2024 Jul;25(4):685-688. doi: 10.1007/s40257-024-00868-x. Epub 2024 May 27.

Authors

Sarah E Thomas¹, Marieke M B Seyger², Josje E Mangnus², Marisol E Otero², Antoni H Gostynski³, Marcellus D Njoo⁴, Paul M Ossenkoppele⁴, Inge M Haeck⁵, Judith H J Hendricksen-Roelofzen⁶, John E M Körver⁷, Sharon R P Dodemont⁸, Ron A Tupker⁹, Maartje A M Berends¹⁰, Lizelotte M J T Weppner-Parren¹¹, Romy R M C Keijsers¹², Annet M Oostveen¹³, Bas Peters¹⁴, Roland Mommers¹⁵, Martijn B A van Doorn¹⁶, Milan Tjioe¹⁷, Wendelien R Veldkamp¹⁸, Astrid L A Kuijpers¹⁹, Marloes M Kleinpenning²⁰, Elke M G J de Jong^{2

21}, Juul M P A van den Reek²

Affiliations

¹ Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands. [email protected].
² Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox 9101, 6500 HB, Nijmegen, The Netherlands.
³ Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands.
⁴ Department of Dermatology, Ziekenhuisgroep Twente, Almelo, Hengelo, The Netherlands.
⁵ Department of Dermatology, Utrecht Medisch Centrum, Utrecht, The Netherlands.
⁶ Department of Dermatology, Streekziekenhuis Koningin Beatrix, Winterswijk, The Netherlands.
⁷ Department of Dermatology, Amphia Ziekenhuis, Breda, The Netherlands.
⁸ Department of Dermatology, Catharina Ziekenhuis, Eindhoven, The Netherlands.
⁹ Department of Dermatology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands.
¹⁰ Department of Dermatology, Slingeland Ziekenhuis, Doetinchem, The Netherlands.
¹¹ Department of Dermatology, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, The Netherlands.
¹² Department of Dermatology, Zuyderland Medisch Centrum, Sittard-Geleen, Heerlen, The Netherlands.
¹³ Department of Dermatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands.
¹⁴ Department of Dermatology, Ziekenhuis Rijnstate, Arnhem, The Netherlands.
¹⁵ Department of Dermatology, Anna Ziekenhuis, Geldrop, The Netherlands.
¹⁶ Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands.
¹⁷ Department of Dermatology, Bravis, Bergen op Zoom, The Netherlands/dermaTeam, Middelburg, The Netherlands.
¹⁸ Department of Dermatology, Ziekenhuis Gelderse Vallei, Ede, The Netherlands.
¹⁹ Department of Dermatology, Máxima MC, Eindhoven, The Netherlands.
²⁰ Department of Dermatology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.
²¹ Radboud University, Nijmegen, The Netherlands.

PMID: 38802618
DOI: 10.1007/s40257-024-00868-x

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use
Adult
Antibodies, Monoclonal, Humanized / therapeutic use
Dermatologic Agents* / therapeutic use
Drug Substitution*
Female
Humans
Interleukin-23* / antagonists & inhibitors
Interleukin-23* / immunology
Male
Middle Aged
Psoriasis* / drug therapy
Psoriasis* / immunology
Retrospective Studies
Severity of Illness Index
Treatment Outcome
Ustekinumab* / therapeutic use

Substances

Ustekinumab
Interleukin-23
Dermatologic Agents
Antibodies, Monoclonal, Humanized
Adalimumab